HCW Biologics is trading at $4.23 (+10.49%) in pre-market, rebounding from its July 20 close of $3.83 amid broader risk-on sentiment and gains in the Nasdaq.
- No company-specific catalysts, such as earnings, FDA updates, or regulatory announcements, were identified to explain the move.
- The sharp jump may also reflect low-float volatility following a period of downward pressure in recent trading sessions.
- The move aligns with a broader market rally as technology stocks see increased bidding and U.S. futures trend higher.